464 related articles for article (PubMed ID: 29550884)
1. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Ceronie B; Jacobs BM; Baker D; Dubuisson N; Mao Z; Ammoscato F; Lock H; Longhurst HJ; Giovannoni G; Schmierer K
J Neurol; 2018 May; 265(5):1199-1209. PubMed ID: 29550884
[TBL] [Abstract][Full Text] [Related]
2. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
Moser T; Schwenker K; Seiberl M; Feige J; Akgün K; Haschke-Becher E; Ziemssen T; Sellner J
Ann Clin Transl Neurol; 2020 Nov; 7(11):2199-2212. PubMed ID: 33002321
[TBL] [Abstract][Full Text] [Related]
3. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
4. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
[TBL] [Abstract][Full Text] [Related]
5. Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms of action related to the efficacy and safety of cladribine.
Baker D; Pryce G; Herrod SS; Schmierer K
Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
9. Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients.
Ruschil C; Gabernet G; Kemmerer CL; Jarboui MA; Klose F; Poli S; Ziemann U; Nahnsen S; Kowarik MC
Front Immunol; 2023; 14():1133967. PubMed ID: 36960053
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine.
Holm Hansen R; von Essen MR; Reith Mahler M; Cobanovic S; Sellebjerg F
Front Immunol; 2024; 15():1327672. PubMed ID: 38433828
[TBL] [Abstract][Full Text] [Related]
11. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
[TBL] [Abstract][Full Text] [Related]
12. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
13. Both cladribine and alemtuzumab may effect MS via B-cell depletion.
Baker D; Herrod SS; Alvarez-Gonzalez C; Zalewski L; Albor C; Schmierer K
Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e360. PubMed ID: 28626781
[TBL] [Abstract][Full Text] [Related]
14. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
[TBL] [Abstract][Full Text] [Related]
15. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
16. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
17. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Rommer PS; Zettl UK
Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
[TBL] [Abstract][Full Text] [Related]
18. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G
Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
[TBL] [Abstract][Full Text] [Related]
19. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
Sellner J; Rommer PS
Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
[TBL] [Abstract][Full Text] [Related]
20. Cladribine Effects on T and B Cells and T Cell Reactivity in Multiple Sclerosis.
Holm Hansen R; von Essen MR; Mahler MR; Cobanovic S; Binko TS; Sellebjerg F
Ann Neurol; 2023 Sep; 94(3):518-530. PubMed ID: 37191113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
